Description of the Copper Concentration in Breast Milk in Women Treated for Wilson's Disease

Wilson's Disease Clinical Trial

— WILLACT  

Official title:

Description of the Copper Concentration in Breast Milk in Women Treated for Wilson's Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05183165
• Other study ID #: AOA_2021_28
• Status: Recruiting
• Phase: N/A
• Start date: May 11, 2022
• Est. completion date: August 2026

Study information

• Verified date: July 2023
• Source: Fondation Ophtalmologique Adolphe de Rothschild
• Contact: Amélie YAVCHITZ
• Phone: 01 48 03 64 54
• Email: ayavhitz[@]for.paris
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Wilson's disease is a rare genetic disease, affecting less than 1,500 people in France. The transmission is autosomal recessive linked to an anomaly of the ATP7B gene on chromosome.This gene codes for an ATPase-type transmembrane protein involved in the transport of copper through the cell plasma member.This gene codes for an ATPase-type transmembrane protein involved in the transport of copper through the cell plasma member. If there is no mutation, this ATPase incorporates copper into apo-ceruloplasmin to be released into the blood serum. The mutation of the ATP7B gene results in a defective biliary excretion of copper, leading to its accumulation in the liver, but also in other organs such as the eye or the brain. Advances in treatment have dramatically changed the prognosis for Wilson's disease, making the desire for pregnancy more confident.

The consensus is to maintain treatment during pregnancy, reducing the dosage to limit teratogenicity as well as the risk of fetal copper deficiency.The mammary gland is the primary site of copper metabolism in lactation, and ATPase 7B is the primary effector.

It has been shown in a mouse model of Wilson's disease (ATP7B - / - mouse) with treatment, that mothers accumulate copper in the liver but also in the mammary gland.

However, a recent study showed that the copper level in breast milk was normal in 18 Wilsonian patients treated with D-penicillamine, trientine salts or zinc salts, suggesting that breastfeeding is possible in these patients without risk to the development of the infants.The problem of breastfeeding newborns for patients with Wilson's disease is therefore associated with a risk of copper deficiency in the newborn due to insufficiently rich breast milk in copper due to drugs.

In addition, the passage into breast milk of treatments is not sufficiently known.

These factors make breastfeeding not currently recommended for Wilsonian mothers,However, many patients wish to breastfeed and some of them breastfeed their newborns despite the risk of breastfeeding

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 15
• Est. completion date: August 2026
• Est. primary completion date: August 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Criteria for inclusion :

• Patient aged 18 years or over.

• Wilson's disease fulfilling the criteria for the Leipzig score

• Pregnancy in progress whatever the term.

• Express consent to participate in the study.

• Affiliate or beneficiary of a social security system.

Criteria for non-inclusion :

• Liver transplant patient

• No affiliation to Social Security system

• VuInability to give free and informed consent

• Patient benefiting from a legal protection measure

Related Conditions & MeSH terms

• Wilson's Disease

Intervention

Other:
• Patients with Wilson's disease declaring pregnancy,
Blood and urine biological assessment Dietary assessment

Locations

Country	Name	City	State
France	Fondation Adolphe de Rothschild	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Fondation Ophtalmologique Adolphe de Rothschild

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Concentration of total copper (bound and free) in µmol / L in a sample of breast milk	The assay is performed by induced plasma mass spectrometry (ICP-MS) after nitric acid mineralization of the sample.; Concentration of total copper (bound and free) in µmol / L in a sample of breast milk taken 1 day ± 24 hours after childbirth.; The copper assay is performed by induced plasma mass spectrometry (ICP-MS) after nitric acid mineralization of the sample.; The copper assay is performed by induced plasma mass spectrometry (ICP-MS) after nitric acid mineralization of the sample.	1 day ± 24 hours after childbirth